at a glance
Nipah virus Infection
01 March 2019 to 31 March 2023
University of Tokyo with European Vaccine Initiative as co-leader
10 Mio US$
The CEPI-funded Nipah vaccine candidate is a live attenuated measles vector-based vaccine containing the Nipah-virus G gene (Malaysia strain). The recombinant vaccine candidate was developed at The Institute of Medical Science, University of Tokyo, and has shown to induce humoral and cellular responses in a preclinical study. In addition, the vaccine protected against lethal nipah virus infection in a hamster and non-human primate model. Process development and manufacturing is under development at Batavia Biosciences.
Batavia Biosciences (Netherlands); European Vaccine Initiative (EVI) (Germany); University of Stanford (USA); University of Tokyo (Japan).
This project has received funding from the Coalition for Epidemic Preparedness Innovations (CEPI).